Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.56 |
| ▸ | NPC1 | O15118 | 9/20 | 0.56 |
| ▸ | GAA | P10253 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16418407 | 0.80 | RAB9A (0.56) | RAB9ANPC1GAASMN1; SMN2MAPT | |
| SCHEMBL25830149 | 0.80 | RAB9A (0.56) | RAB9ANPC1GAASMN1; SMN2MAPT | |
| SCHEMBL12726207 | 0.80 | RAB9A (0.56) | RAB9ANPC1GAASMN1; SMN2MAPT | |
| SCHEMBL25234452 | 0.79 | RAB9A (0.56) | RAB9ANPC1GAASMN1; SMN2MAPT | |
| SCHEMBL30864974 | 0.77 | RAB9A (0.53) | RAB9ANPC1GAASMN1; SMN2MAPT | |
| SCHEMBL7522459 | 0.77 | RAB9A (0.76) | RAB9ANPC1GAASMN1; SMN2MAPT | |
| SCHEMBL29631623 | 0.77 | PAX8 (0.65) | RAB9ANPC1GAASMN1; SMN2MAPT | |
| SCHEMBL3114355 | 0.77 | RAB9A (0.53) | RAB9ANPC1GAASMN1; SMN2MAPT | |
| SCHEMBL3114363 | 0.77 | RAB9A (0.53) | RAB9ANPC1GAASMN1; SMN2MAPT | |
| SCHEMBL8342118 | 0.77 | PAX8 (0.65) | RAB9ANPC1GAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150174-A1 | CONDITIONALLY ACTIVATED IMMUNOCYTOKINES AND METHODS OF USE | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20230250181-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230201365-A1 | MODIFIED CD20 ANTIBODIES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230201364-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230183331-A1 | MODIFIED TNF-ALPHA ANTIBODIES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230181754-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| WO-2023281483-A1 | MODIFIED TNF-ANTIBODIES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023281481-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | BRIGHT PEAK THERAPEUTICS (CH) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023281484-A1 | SYNTHETIC IL-7 AND IL-7 IMMUNOCYTOKINES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023281482-A1 | CD20-TARGETED IL-2 AND ITS USES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | IL18, CD74, IL2 | RAB9A 1609/4885NPC1 3194/4885GAA 942/4885 |
| US-20230250181-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | PDCD1, CD274, PDCD1LG2 | RAB9A 2647/4885NPC1 4003/4885GAA 596/4885 |
| US-20230201364-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | CD2BP2, CD47, BCR | RAB9A 953/4885NPC1 3522/4885GAA 1007/4885 |
| US-20230201365-A1 | MODIFIED CD20 ANTIBODIES AND USES THEREOF | CD209, CD22, CD47 | RAB9A 1057/4885NPC1 3387/4885GAA 632/4885 |
| US-20230181754-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | PDCD1LG2, CD274, PDCD1 | RAB9A 2554/4885NPC1 4566/4885GAA 1276/4885 |
| US-20230183331-A1 | MODIFIED TNF-ALPHA ANTIBODIES AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | RAB9A 2449/4885NPC1 4288/4885GAA 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.